Catalent To Open New Clinical Supply Facility In San Diego
Will Enhance Speed to Clinic through Expanded Early-Phase Clinical Supply and Oral Dose Development Services
SOMERSET, N.J. – September 5, 2019 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced it is to invest $9 million in a new clinical supply facility in San Diego, due to open in the summer of 2020.
The new 24,257 square-feet facility will offer full clinical supply services to pharmaceutical and biopharmaceutical customers and will specialize in services for early-phase clinical trials. Its capabilities will include clinical supply management, primary and secondary packaging, complex labeling services, clinical storage, distribution, and drug returns and destruction, and will include stability chambers.
Located less than a mile from the company’s West Coast early-phase oral drug product development center of excellence, the new facility enhances Catalent’s OptiForm® Total Supply service, offering customers fully integrated development, clinical supply manufacturing and distribution. This integrated approach helps customers minimize overall project risks and can significantly reduce the time taken to move a program from development into clinic.
“This investment supports Catalent’s commitment to offering customers greater flexibility and expanded support for early-phase studies” commented Paul Hegwood, President, Clinical Supply Services. “The facility will allow Catalent to provide superior clinical services throughout the western corridor of the U.S. and Canada’s drug development region.”
With sites in the U.S., U.K., Germany, Singapore, Japan and China, and an extended network of over 50 depots, Catalent’s clinical supply services team has the capability and expertise to handle a broad range of international compliance and distribution requirements, and so help to expedite clinical trials by ensuring customers are reliably supplied where and when needed around the globe.
Catalent’s existing San Diego facility is one of three global centers of excellence in oral dose early-phase development focusing on preclinical to clinical Phase 2b formulation, analytical, and manufacturing solutions for orally delivered small molecules, the other two being in Somerset, New Jersey and Nottingham, U.K.
For further information on Catalent’s Clinical Supply Services business visit www.clinical.catalent.com .
+44 (0)7580 041073
+44 (0) 161 728 5880
Notes for Editors
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including over 2,400 scientists, at more than 35 facilities across five continents, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com